Merck & Co. is recalling 39,000 doses of a vaccine against measles, mumps, and rubella because it was shipped before the company finished an internal approval process.
Federal regulators have denied Johnson & Johnson's request to expand approval of Xarelto for a new use preventing life-threatening blood clots in high-risk patients.
Link Technologies Ltd has launched two modified phosphoramidite ranges to complement its existing extensive portfolio of products to support oligonucleotide synthesis.
Phenomenex Inc. introduces Yarra—a family of aqueous size exclusion chromatography (SEC) columns for biomolecule analysis.
Thermo Fisher Scientific Inc. has introduced the UltiMate 3000 XRS UHPLC system, offering advanced solvent delivery and sample handling with a range of detector options.
New classes of drugs target the androgens that prostate cancer thrive off in novel ways, providing alternatives to traditional methods that often carry high side effects.
Researchers have discovered that a single protein may hold the key to turning cardiac stem cells into blood vessels or muscle tissue.
The University of Washington has begun enrolling patients in a Phase 2 study testing Cell Therapeutics' tosedostat in elderly patients with acute myeloid leukemia.
Raptor Pharmaceutical Corp. has finished enrollment for its Phase 2/3 clinical trial of RP103 for the potential treatment of Huntington's disease.
Two research groups are using Population Genetics Technologies to enable studies on gene variants associated with myocardial infarction, diabetes, and metabolic disease.
AstraZeneca PLC said that it completed its $1.26 billion acquisition of gout drug developer Ardea Biosciences Inc.
Hepatitis C drug developer Idenix Pharmaceuticals Inc. has reported promising results from a mid-stage study of a potential treatment.
A judge has denied a request for a new trial after he fined Johnson & Johnson and a subsidiary $1.2 billion for downplaying and concealing risks associated with Risperdal.
A panel of cancer specialists endorsed a potential blood cancer treatment from Ligand Pharmaceuticals' development partner, Onyx Pharmaceuticals.